Cryo Cell International Inc: Form 10-K for the period ended Nov 30, 2018
Filed with the SEC on Feb 28, 2019 and accepted by EDGAR at Feb 28, 2019, 22:18 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-11-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2017-12-01 to 2018-11-30 | $29.2m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 12 months2017-12-01 to 2018-11-30 | $8.5m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 12 months2017-12-01 to 2018-11-30 | $91.8k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2017-12-01 to 2018-11-30 | $15.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2017-12-01 to 2018-11-30 | $5.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2017-12-01 to 2018-11-30 | $1.5m | us-gaap:InterestExpense |
| Income tax | 12 months2017-12-01 to 2018-11-30 | $4.5m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2017-12-01 to 2018-11-30 | −$854.8k | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2017-12-01 to 2018-11-30 | −$0.11 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2017-12-01 to 2018-11-30 | −$0.11 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2017-12-01 to 2018-11-30 | 7,463,051 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2017-12-01 to 2018-11-30 | $5.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2017-12-01 to 2018-11-30 | $446.2k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2018-11-30 | $6.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2018-11-30 | $29.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2018-11-30 | $42.4m | us-gaap:Assets |
| Current liabilities | At period end2018-11-30 | $15.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2018-11-30 | $51.3m | us-gaap:Liabilities |
| Long-term debt | At period end2018-11-30 | $1.4m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2018-11-30 | −$8.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001193125-19-057945. Last ingested by Listed: Oct 24, 2026, 14:58 ET. Listed shows no prices and gives no investment advice.